

GLAXOSMITHKLINE PLC

Form 6-K

November 18, 2011

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending November 2011

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--



Notifiable Share Interest in OctoPlus N.V.

GlaxoSmithKline plc ("GSK") announces that following a private placement offering made by OctoPlus N.V. ("OctoPlus"), a pharmaceuticals product and drug delivery company located in the Netherlands and whose shares are traded on Euronext Amsterdam, on 26 October 2011, GSK's interest in OctoPlus has decreased.

GSK's interest, which is held by S.R. One, Limited, a wholly owned US-registered subsidiary of GSK ("S.R.One"), now comprises 4,345,062 ordinary shares or 9.7% of OctoPlus. The calculation is based on a total of 44,778,974 shares outstanding in OctoPlus. This decreased interest became disclosable under the rules of the Dutch Financial Supervision Act upon falling below 10% of the issued share capital of OctoPlus, and a notification regarding this decreased holding is due to be made to the Netherlands Authority for the Financial Markets ("AFM") on 18 November 2011.

Victoria Whyte  
Company Secretary

18 November 2011

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: November 18, 2011

By: VICTORIA WHYTE  
-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc